Bryan Roberts, Ph.D. is a partner with Venrock. He joined Venrock as a Kauffman Fellow in 1997. He is based in Venrock's Palo Alto office and focuses on a broad range of healthcare investments. Bryan currently serves on the Board of Directors of Ironwood (NASDAQ: IRWD), as well as a number of private companies including Achaogen, Coderyte, Fate Therapeutics, Ikaria, Satiety and Ventana. Past investments include athenahealth (NASDAQ: ATHN), Xenoport (NASDAQ: XNPT); Sirna Therapeutics (acquired by Merck) and Illumina (NASDAQ: ILMN). Immediately prior to joining Venrock, Bryan received his Ph.D. in Chemistry & Chemical Biology from Harvard University. He previously held positions in corporate finance at Kidder, Peabody & Co and received his B.A. from Dartmouth College. Bryan was named a Henry Crown Fellow by the Aspen Institute in 2006, he was named to healthspottr's 2009 Future Health 100 list and was the highest-ranking healthcare investor on Forbes' Midas List in 2008 and 2009.